Skip to main content
Request for proposal

A spray as a shield: a new step by Leyden Labs in virus prevention

Scroll down

How effective is the intranasal delivery of antibodies, according to recent research from Leyden Labs?

| Leiden Bio Science Park

Leyden Labs, located at the Leiden Bio Science Park, is developing a new way to protect people against diseases such as influenza and other respiratory viruses. In this study, the researchers used a nasal spray containing antibodies, instead of administering them via traditional injections. 

Nasal spray as a new line of defence against viruses

Viruses like influenza and COVID-19 typically enter the body through the nose or mouth. That's why Leyden Labs is investigating whether antibodies can be delivered directly to the nasal mucosa using a spray - right at the point where the virus first enters. Recent studies suggest that this intranasal approach may help neutralise viruses at an early stage, before they can spread throughout the body. A promising step toward new forms of prevention. 

  • An accessible and efficient approach

    The study showed that the nasal spray containing antibodies requires a lower dosage than an injection. This is good news, as the fewer antibodies needed to produce a product, the more can be manufactured and the lower the production costs become. Additionally, the nasal spray is easier to use, as it may in future be self-administered by the patient, unlike an injection or infusion, which must be given by a nurse.

  • Also effective for people with weakened immune systems

    The effectiveness of the nasal spray appears to be independent of the immune system. The study looked at two components of antibodies: the Fab region, which recongnises viruses, and the Fc region, which normally activates the immune system. Results showed that only the Fab region is needed for the spray to work. This so-called Fc-independence means the approach could also be effective in people with a weakened immune system. 

  • CR9114: one antibody, broad protection

    Leyden Labs has obtained an exclusive licence from Janssen Pharmaceutica to further develop the CR9114 antibody for use in a nasal spray. CR9114 is capable of recognising multiple types of influenza viruses - including A, B, C, and D - and thus offers broad-spectrum protection suitable for various flu seasons. Even in the case of virus mutations, the antibody remains effective according to the research. By combining broad protection with accessible delivery, this innovation could become a valuable tool in combatting future viral outbreaks.

Future research: from lab to large-scale application

The findings represent a valuable step within the PanFlu programme, which focuses on preparedness for future viral outbreaks. According to Clarissa Koch, Chief Research Officer at Leyden Labs, the results offer important insights for follow-up research. Professor of Virology Nigel Temperton also highlights the significance of this study: not just the antibody itself, but particularly the method of delivery plays a crucial role in the effectiveness of virus prevention. As such, the implications of this research go beyond influenza alone - and underline the innovative work being done in Leiden, at the very heart of the Leiden Bio Science Park. 

Read more?

This website uses cookies

This website uses cookies (Functional, Analytical, Marketing) that are required for the website to perform as good as possible. By clicking on "I accept all cookies", you agree with the use of these cookies.